RUTHERFORD, NJ – October 30, 2014 – Cancer Genetics, Inc. (NasdaqCM: CGIX), an emerging leader in DNA-based cancer diagnostics, announced today that it will report third quarter 2014 financial results on Monday, November 10, 2014.  The Company will issue a press release before the market opens and will host a conference call at 8:30am Eastern Standard Time to discuss the third quarter financial results and to answer questions.

 

Conference Call & Webcast

Monday, November 10, 2014 at 8:30 a.m. EST/5:30 a.m. PST

Domestic:                               877-407-4018
International:                       201-689-8471
Conference ID:                      13594358
Webcast:                                 http://www.cancergenetics.com

 

Replays – Available through November 24, 2014

Domestic:                                  877-870-5176
International:                           858-384-5517
Conference ID:                         13594358

 

About Cancer Genetics

Cancer Genetics Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute.

For more information, please visit www.CancerGenetics.com, or follow Cancer Genetics on twitter @Cancer_Genetics.

Contact:

Investor Relations
Andrew McDonald
Life Science Advisors LLC
646-597-6987
paul@redchip.com

 

Media Relations
Paul Kuntz
RedChip Companies, Inc.
800-733-2447, ext. 105